TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29636042
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of insulin, having some problems with T2D self-care, coffee consumption
Study: 29636983
Drug: Hip muscle
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip muscle strengthening and core stabilization program (10 sessions, twice a week for 6 weeks)
Study: 29636984
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein supplement (120 mmol of solutes, allowing an extra 163 mL free water loss) for 4 weeks
Study: 29636984
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein supplement
Study: 29637088
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (minimum 12 hours) followed by oral antibiotics (total course 10 days)
Study: 29638161
Drug: High Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High Insulin Studies (HISs)
Study: 29638161
Drug: Low Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Insulin Studies (LISs)
Study: 29641297
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg on a 2/1 schedule
Study: 29641374
Drug: Medication monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitoring sensors
Study: 29643053
Drug: Mobile app
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app intervention with daily questionnaires
Study: 29643063
Drug: Prexasertib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prexasertib, a Checkpoint Kinase 1 Inhibitor
Study: 29645077
Drug: Risk model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk model for predicting colorectal cancer (CRC) based on clinical characteristics including rectal bleeding, weight loss, and changes in bowel habits.
Study: 29645077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal bleeding with weight loss and changes in bowel habits.
Study: 29649027
Drug: Pain interference
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain interference with daily life
Study: 29649885
Drug: S-amlodipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine 2.5 mg/d
Study: 29649885
Drug: S-amlodipine 5
Normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine 5 mg/d
Study: 29649885
Drug: Previous antihypertensive
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous antihypertensive medications
Study: 29650362
Drug: Tazemetostat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazemetostat (100 mg to 1600 mg twice daily)
Study: 29650362
Drug: Tazemetostat (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazemetostat (800 mg twice daily)
Study: 29652795
Drug: HIV protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV protease inhibitor (PI)
Study: 29653643
Drug: High-density lipoprotein
Normalized name: Cholesterol in High-density lipoprotein (HDL) 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density lipoprotein cholesterol levels >40 mg/dL for men and >50 mg/dL for women
Study: 29653643
Drug: Glucose levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose levels <100 mg/dL
Study: 29654023
Drug: Gemcitabine-included doublet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-included doublet chemotherapy
Study: 29654485
Drug: Tocilizumab (TCZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (TCZ), 8 mg/kg, intravenous infusion every 4 weeks
Study: 29654720
Drug: Anticoagulant use
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant use
Study: 29655061
Drug: Chemotherapy ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy ± maintenance endocrine therapy
Study: 29655489
Drug: Cochleural Alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochleural Alternating Acoustic Beam Therapy (CAABT) for 12 weeks
Study: 29655662
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin anti-coagulation (INR target 1.5 to 1.9)
Study: 29655877
Drug: Spironolactone 25-50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25-50 mg
Study: 29655877
Drug: Amiloride 10-20
Normalized name: amiloride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10-20 mg
Study: 29655877
Drug: Bisoprolol 5-10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5-10 mg
Study: 29655877
Drug: Doxazosin 4-8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4-8 mg
Study: 29656846
Drug: NDI-G
Normalized name: NDI-5001
DrugBank: NDI-5001 (DB17609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDI-G
Study: 29657831
Drug: Verinurad 2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 2.5-20 mg in combination with febuxostat (40 or 80 mg)
Study: 29657831
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 or 80 mg) alone
Study: 29657831
Drug: Verinurad administered
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad administered with febuxostat
Study: 29658848
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) administered intravenously every 2 weeks for 2 doses before surgery
Study: 29658962
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing 291 kcal/d for young children and 350 kcal/d for older children, administered 5 days/week for 11 weeks.
Study: 29659102
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for GAD
Study: 29659102
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for PD
Study: 29659102
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for SAD
Study: 29659102
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for OCD
Study: 29659102
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for PTSD
Study: 29659102
Drug: Antidepressants across
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants across severity levels for SAD
Study: 29659102
Drug: Antidepressants across
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants across severity levels for OCD
Study: 29659102
Drug: Antidepressants across
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants across severity levels for PTSD
Study: 29659330
Drug: DD4A chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD4A chemotherapy (vincristine/dactinomycin/doxorubicin) without lung radiation therapy for patients with CR.
Study: 29659330
Drug: DD4A chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD4A chemotherapy plus lung radiation therapy and four cycles of cyclophosphamide/etoposide for patients with IR.
Study: 29659330
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment strategy of AREN0533.
Study: 29659889
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (ECP) with higher anti-EBOV antibody levels
Study: 29659889
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (ECP) with lower anti-EBOV antibody levels
Study: 29659964
Drug: Universal salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal salt iodization (USI) with salt iodine concentration at ∼25 mg/kg
Study: 29660005
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (Cabozantinib monotherapy)
Study: 29661508
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment upon disease progression to Gleason 7 (3+4)
Study: 29661508
Drug: Consensus on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus on follow-up protocols and active treatment criteria
Study: 29661699
Drug: Sacubitril/valsartan (97
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (97 mg/103 mg twice daily)
Study: 29662875
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based second-line regimen with adherence counseling for 3 months
Study: 29662960
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene discontinuation for 10 days
Study: 29664672
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care management of sleep apnea, details on dosage and duration not available
Study: 29664672
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for sleep apnea, details on dosage and duration not available
Study: 29664709
Drug: G1XCGD, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1XCGD, a lentiviral vector for ex vivo gene therapy
Study: 29665842
Drug: Sensory re-learning
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory re-learning in combination with task-specific training
Study: 29665840
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A pretreatment (2.5 mg/kg) in deceased organ donors
Study: 29666296
Drug: Rilotumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (20 mg/kg) and Bevacizumab (10 mg/kg) every 2 weeks
Study: 29666297
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of everolimus by mouth (PO) weekly
Study: 29666297
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of everolimus PO daily
Study: 29667940
Drug: Saphenous nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous nerve block with 10 mL 0.5% bupivacaine with 1:200,000 epinephrine
Study: 29667940
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving 10 mL saline
Study: 29668600
Drug: Promoter methylation
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promoter methylation analysis for selected genes and tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2).
Study: 29669391
Drug: Fostamatinib (a
Normalized name: fostamatinib (as disodium hexahydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (a small molecule inhibitor of Syk)
Study: 29669701
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg twice per day (oral) on a continuous daily dosing schedule for 21 days until disease progression, unacceptable toxicity, or patient refusal.
Study: 29669753
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg orally daily
Study: 29669753
Drug: Ibrutinib 840
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 840 mg orally daily
Study: 29669753
Drug: Ibrutinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (both doses)
Study: 29669936
Drug: HPV-16 E7-specific
Normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16 E7-specific TCR T cell therapy
Study: 29670761
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q4W
Study: 29672891
Drug: Glecaprevir/pibrentasvir (300/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks
Study: 29673370
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of renal replacement therapy (RRT) within 6 hours
Study: 29673370
Drug: Standard initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation of renal replacement therapy (RRT) by urgent indication
Study: 29673379
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 40,000 IU/ml
Study: 29673381
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly monitoring survey)
Study: 29673890
Drug: FDC drug
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin)
Study: 29673942
Drug: Tick-borne encephalitis
Normalized name: Tick-borne encephalitis vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tick-borne encephalitis (TBE) booster vaccine
Study: 29675856
Drug: PKC inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC inhibitor GF 109203X
Study: 29675856
Drug: Rho kinase
Normalized name: Rho(D) immune globulin Injection [WinRho]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rho kinase inhibitor Y-27632
Study: 29675856
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention of PKC inhibitor and Rho kinase inhibitor
Study: 29677353
Drug: Subretinal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal delivery (high dose: 1 × 10^12 vg)
Study: 29677353
Drug: Subretinal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal delivery (low dose: 1 × 10^11 vg)
Study: 29678146
Drug: Chemotherapy including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy including S-1 (IS)
Study: 29678146
Drug: Chemotherapy not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy not including S-1 (NIS)
Study: 29678476
Drug: Cabazitaxel plus
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel plus Lapatinib (intravenous cabazitaxel 20 mg/m²)
Study: 29678804
Drug: iWaWa treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: iWaWa treatment (8 weeks)
Study: 29680880
Drug: PRO-122 (preservative-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-122 (preservative-free fixed combination)
Study: 29680880
Drug: KOF (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOF (0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination)
Study: 29681490
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter)
Study: 29681973
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy
Study: 29681973
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Massage Therapy and Abdominal Hypopressive Gymnastics
Study: 29682131
Drug: Noninvasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive therapy using a biostimulation laser over 12 sessions performed every second day
Study: 29682332
Drug: ALK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK inhibitors
Study: 29682332
Drug: Anti-PD1 inhibitors
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD1 inhibitors
Study: 29682773
Drug: Hydrocortisone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (higher daily doses)
Study: 29683544
Drug: High-dosed folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosed folate supplements (5 mg folic acid per day)
Study: 29683544
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (200 mg ferrous sulphate per day)
Study: 29683562
Drug: Oral osimertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral osimertinib 80 mg
Study: 29683562
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) osimertinib 100 μg microtracer dose
Study: 29684022
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ceftriaxone and azithromycin
Study: 29684022
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ceftriaxone
Study: 29684022
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of azithromycin and cefexime
Study: 29684022
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with azithromycin
Study: 29685594
Drug: Vaxem™ Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxem™ Hib (intramuscular injection)
Study: 29686173
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment for diabetes
Study: 29687077
Drug: Single-injection intrathecal
Normalized name: ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-injection intrathecal analgesia (IA)
Study: 29689135
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9mg/kg)
Study: 29689485
Drug: High-dose dronabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dronabinol (180-240 mg/day; 60-80 mg tid)
Study: 29689485
Drug: Low-dose dronabinol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dronabinol (120 mg/day; 40 mg tid)
Study: 29690880
Drug: Lower forced
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower forced expiratory volume in one second after bronchodilator
Study: 29691182
Drug: Adjunctive protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive protective drapes
Study: 29691182
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive protective drapes (implied control)
Study: 29691270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations.
Study: 29691270
Drug: hs-cTnI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI and hs-cTnT concentrations with optimized cut-off values (sum: 9 ng/L, product: 18 ng/L).
Study: 29692980
Drug: NCI-sponsored uterine
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NCI-sponsored uterine cervix cancer radiation-chemotherapy intervention clinical trial (NCT02466971)
Study: 29693476
Drug: Amoxicillin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1500 mg/d for 7 days)
Study: 29693476
Drug: Vancomycin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1500 mg/d for 7 days)
Study: 29693476
Drug: Placebo (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1500 mg/d for 7 days)
Study: 29695165
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 75 mg BID for ≥7 days
Study: 29695384
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (thrombectomy, balloon angioplasty, stenting, local fibrinolysis, piercing)
Study: 29695384
Drug: No endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endovascular therapy
Study: 29695516
Drug: INCB040093 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB040093 100 mg twice daily (monotherapy)
Study: 29695516
Drug: INCB040093 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination)
Study: 29696202
Drug: Topical antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antiviral drug AV2
Study: 29696238
Drug: Gender- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender- and culturally-sensitive weight loss intervention (GCSWLI) for 24 weeks, including a 12-week in-person phase with weekly sessions and a 12-week follow-up with bi-weekly phone calls.
Study: 29699493
Drug: Non-adherent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherent treatment (62.1% of patients)
Study: 29699493
Drug: Over-treatment in
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-treatment in general-ward patients (52.3% over-treated)
Study: 29699493
Drug: Under-treatment in
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under-treatment in ICU patients (71.4% under-treated)
Study: 29699493
Drug: Under-treatment in
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under-treatment in general-ward patients with risk factors for PA infection (22.9% under-treated)